Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | PDE6D | O43924 | 1/20 | 0.30 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060482 | 0.83 | TP53 (0.39) | TP53BRD4QPCTL | |
| SCHEMBL5625197 | 0.74 | PDE2A (0.45) | TP53BRD4GRM2PDE2A | |
| SCHEMBL3049300 | 0.73 | TP53 (0.39) | TP53BRD4RPS6KA5 | |
| SCHEMBL3064280 | 0.72 | CYP11B2 (0.48) | AOC3RPS6KA5 | |
| SCHEMBL5624950 | 0.72 | PPARG (0.42) | TP53BRD4GRM2RPS6KA5 | |
| SCHEMBL3062910 | 0.71 | GRIN2B (0.42) | — | |
| SCHEMBL3065554 | 0.71 | RPS6KA5 (0.42) | AOC2BRD4NPY5RGRM2RPS6KA5 | |
| SCHEMBL3072991 | 0.70 | GRM2 (0.47) | TP53GRM2PDE6D | |
| SCHEMBL3062898 | 0.70 | GRM5 (0.43) | TP53BRD4GRM2PDE2A | |
| SCHEMBL3065442 | 0.70 | AGTR1 (0.39) | TP53GRM2RPS6KA5PDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | AOC2 1137/4885TP53 4833/4885BRD4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.